Cellectis S.A. (EPA:ALCLS)

-43.02% (1Y)

Market Cap	100.64M
Revenue (ttm)	47.54M
Net Income (ttm)	-35.51M
Shares Out	72.09M
EPS (ttm)	-0.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,098
Average Volume	173,114
Open	1.420
Previous Close	1.390
Day's Range	1.390 - 1.420
52-Week Range	1.012 - 3.025
Beta	3.38
RSI	56.76
Earnings Date	May 7, 2025

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 222
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCLS

Financial Performance

In 2024, Cellectis's revenue was $49.22 million, an increase of 435.37% compared to the previous year's $9.19 million. Losses were -$36.76 million, -63.62% less than in 2023.

Financial numbers in USD